secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001193125-24-054312
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences Q4 revenue up 21% to $58.6M; full year net loss $11.3M; guides 5-10% growth for 2024
--------------------------------------------------------------------------------

- Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).
- Q4 net income $6.3M vs $3.7M; full year net loss $11.3M vs income $2.5M.
- 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income.
- Repurchased 5.3M shares for $34.7M in Q4; 6.6M total since May 2023.
- Introduced Cytek Orion automated antibody cocktail prep system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/d781057d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-054312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer